GS010 for Leber hereditary optic neuropathy demonstrated quality of life improvements in a phase 3 clinical trial, GenSight Biologics announced in a press release.
The phase 3 REVERSE trial evaluated the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 37 patients with LHON.
Each subject completed the National Eye Institute Visual Function Questionnaire-25, which measures a patient’s perception of his ability to perform daily activities requiring high-acuity vision, the release said.
Patients in the trial reported an improvement in near activities, distance
Uncategorized